Metabolic & Obesity Care

Structural racism and inequity in global diabetes care; obesity & cancer risk; lawsuits against compounded GLP-1s; and, the end of BMI

Structural racism and inequity in global diabetes care; obesity & cancer risk; lawsuits against compounded GLP-1s; and, the end of BMI???

Hello all, I hope everyone is having a terrific weekend! We are quite excited here at twenty30 health, as we will be attending the annual conference of the American Society of Metabolic and Bariatric Surgery (ASMBS) in Las Vegas this week, in force; see more below. We look forward to connecting with colleagues and friends, old […]

Structural racism and inequity in global diabetes care; obesity & cancer risk; lawsuits against compounded GLP-1s; and, the end of BMI??? Read More »

GLP-1s and addiction, employers push back on GLP-1 cost implications, racial bias, obesity and prostate cancer, and more.

GLP-1s and addiction, employers push back on GLP-1 cost implications, racial bias, obesity and prostate cancer, and more.

AT A GLANCE The 30th European Congress on Obesity [or ECO] was held in Dublin, Ireland this past week, with keynote sessions and scientific presentations. Omada Health, Found Health and Virta Health, synchronously announced their direct-to-employer offerings on care for people with obesity, in a clear call from employers on the cost and long-term durability of GLP-1 medications. Medicare coverage of obesity treatments, and the potential

GLP-1s and addiction, employers push back on GLP-1 cost implications, racial bias, obesity and prostate cancer, and more. Read More »

The call for multimodal obesity care gets louder, obesity in Black America, data on Covid-19 and obesity perspectives across metabolic and obesity care – 514

The call for multimodal obesity care gets louder, obesity in Black America, data on Covid-19 and obesity: perspectives across metabolic and obesity care – 5/14

AT A GLANCE… World Health Organization’s says Wegovy and other weight-loss drugs are ‘…not a silver bullet.’ A seeming shift in the narrative this week toward multimodal, whole-person, and multi-year strategies of care; challenging current direct to consumer, medication-first approaches. Benjamin Chavis Jr., an African-American civil rights leader, writes in The Miami Times on ‘Obesity is not a hopeless fight for

The call for multimodal obesity care gets louder, obesity in Black America, data on Covid-19 and obesity: perspectives across metabolic and obesity care – 5/14 Read More »

Kids juice company begins, nutrition company ends, cancer and obesity, GLP-1 hype [of course] and more perspectives across metabolic and obesity care – 57

Kids juice company begins, nutrition company ends, cancer and obesity, GLP-1 hype [of course] and more: perspectives across metabolic and obesity care – 5/7

AT A GLANCE… Plezi Nutrition, a kids juice drink company, was launched by former First Lady Michelle Obama this week; Ms. Obama is the prior architect of the Let’s Move program. Jenny Craig, a forty year old, nutrition-forward weight loss company with over 1,000 stores, formally announced ‘…It’s with a heavy heart, we’re announcing the close of our business.’

Kids juice company begins, nutrition company ends, cancer and obesity, GLP-1 hype [of course] and more: perspectives across metabolic and obesity care – 5/7 Read More »

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity perspectives across metabolic and obesity care – 430

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity: perspectives across metabolic and obesity care – 4/30

AT A GLANCE… At the Fortune Brainstorm Health conference, I put Chelsea Clinton on the spot for her suggestions to manage the looming four billion people across the globe who will be living with obesity by the year 2035. In The Atlantic, Yasmin Tayag leads with ‘We’ve had a cheaper, more potent Ozempic alternative for decades…’ on bariatric surgery ‘…to be the

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity: perspectives across metabolic and obesity care – 4/30 Read More »

Ongoing obsession with GLP-1 drugs, bariatric surgery improves lives for adolescents and those with liver disease, and more: perspectives across metabolic and obesity care – 4/23

AT A GLANCE… GLP-1 drugs continue to hit the headlines, with United Health Group CEO Andrew Witty weighing in on their benefit and usage. Pregnancy risks of GLP-1 meds – very low likelihood, though currently unknown beyond animal studies. Teledoc strides into GLP-1 space; and Ro founder Zachariah Reitano publishes a long piece on the scientific basis of obesity management with respect to

Ongoing obsession with GLP-1 drugs, bariatric surgery improves lives for adolescents and those with liver disease, and more: perspectives across metabolic and obesity care – 4/23 Read More »

Fast growth, even faster pivots in the GLP-1 space Perspectives across metabolic and obesity care – 416

Fast growth, even faster pivots in the GLP-1 space? Perspectives across metabolic and obesity care – 4/16

AT A GLANCE… Calibrate, a telehealth GLP-1 prescription machine, reports an 18% reduction in workforce, with a move to employer-based contracts. Legacy weight loss companies focused upon behavior change, counting calories and low-carb diets are in a quandary whether to embrace anti-obesity medications. Prediabetes currently affects 1 in 3 adult Americans and is projected to impact over one billion people across

Fast growth, even faster pivots in the GLP-1 space? Perspectives across metabolic and obesity care – 4/16 Read More »

Beyond BMI, military struggles with obesity, and more: perspectives across metabolic and obesity care – 4/9

I wish everyone a Happy Easter if you celebrate and happy weekend if you do not 🙂 AT A GLANCE… Beyond BMI – a high-profile academic committee gets together this week to debate and define the role of BMI as a measure of obesity and health. The U.S. military is struggling with recruitment and lost workdays of their soldiers due to

Beyond BMI, military struggles with obesity, and more: perspectives across metabolic and obesity care – 4/9 Read More »

WHO, GLP-1s and more perspectives across metabolic and obesity care – 42

WHO, GLP-1s and more: perspectives across metabolic and obesity care – 4/2

AT A GLANCE… New data on Rybelsus oral GLP-1 medication from Novo Nordisk, in addition to newbie GLP-1/GIP medication [akin to Mounjaro from Eli Lilly] from Viking Therapeutics, code-named VK2735. The anti-obesity medication market is hotting up, with aligned stock price increases across the board. Are anti-obesity medications the next frontier in saving millions of lives across the globe,

WHO, GLP-1s and more: perspectives across metabolic and obesity care – 4/2 Read More »

Copycat GLP-1s and more perspectives across metabolic and obesity care – 326

Copycat GLP-1s and more: perspectives across metabolic and obesity care – 3/26

AT A GLANCE… Copycat, compounded drugs for weight loss – multiple stories here, here and here. Altimmune presents an interim analysis this week on 160 subjects in the MOMENTUM Phase 2 Obesity Trial. Higher plasma caffeine concentrations were associated with lower body mass index and fat mass, as well as a lower risk of type 2 diabetes. EVENTS Not a ton of excitement

Copycat GLP-1s and more: perspectives across metabolic and obesity care – 3/26 Read More »

Scroll to Top
Skip to content